TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07793929: A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide

Sponsor: Kailera · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 32 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$1,219,104

Rescue Site Savings

+$812,736

Unlock Full NCT07793929 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07793929 Rescue Dossier →